The DOI matches its Crossref record; 377 of the 377 references it cites were found in a registry or an index.
Targeting Transcription Factors for Cancer Treatment
Open accessAbstract
Transcription factors are involved in a large number of human diseases such as cancers for which they account for about 20% of all oncogenes identified so far. For long time, with the exception of ligand-inducible nuclear receptors, transcription factors were considered as “undruggable” targets. Advances knowledge of these transcription factors, in terms of structure, function (expression, degradation, interaction with co-factors and other proteins) and the dynamics of their mode of binding to DNA has changed this postulate and paved the way for new therapies targeted against transcription factors. Here, we discuss various ways to target transcription factors in cancer models: by modulating their expression or degradation, by blocking protein/protein interactions, by targeting the transcription factor itself to prevent its DNA binding either through a binding pocket or at the DNA-interacting site, some of these inhibitors being currently used or evaluated for cancer treatment. Such different targeting of transcription factors by small molecules is facilitated by modern chemistry developing a wide variety of original molecules designed to specifically abort transcription factor and by an increased knowledge of their pathological implication through the use of new technologies in order to make it possible to improve therapeutic control of transcription factor oncogenic functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
NRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
A census of human transcription factors: function, expression and evolution
Vaquerizas, J. M., Kummerfeld, S. K., Teichmann, S. A., & Luscombe, N. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2538 · Cited by 1,573
Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation
Viatour, P., Merville, M.-P., Bours, V., & Chariot, A. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.009 · Cited by 1,496
Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., & Leder, P. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7837 · Cited by 1,422
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
Co-crystal structure of TBP recognizing the minor groove of a TATA element
Kim, J. L., Nikolov, D. B., & Burley, S. K. (1993) · Nature · doi:10.1038/365520a0 · Cited by 1,048
Diversity and Complexity in DNA Recognition by Transcription Factors
Badis, G., Berger, M. F., Philippakis, A. A., Talukder, S., Gehrke, A. R., Jaeger, S. A., Chan, E. T., Metzler, G., Vedenko, A., Chen, X., et al. (2009) · Science · doi:10.1126/science.1162327 · Cited by 990
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Regulation of heat shock transcription factors and their roles in physiology and disease
Gomez-Pastor, R., Burchfiel, E. T., & Thiele, D. J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.73 · Cited by 849
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation
Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G. M., Pasche, A.-C., Knabenhans, C., MacDonald, H. R., & Trumpp, A. (2004) · Genes & Development · doi:10.1101/gad.313104 · Cited by 823
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Gabay, M., Li, Y., & Felsher, D. W. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014241 · Cited by 818
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Sorensen, P. H. B., Lessnick, S. L., Lopez-Terrada, D., Liu, X. F., Triche, T. J., & Denny, C. T. (1994) · Nature Genetics · doi:10.1038/ng0294-146 · Cited by 747
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
An atlas of combinatorial transcriptional regulation in mouse and man
Ravasi, T., Suzuki, H., Cannistraci, C. V., Katayama, S., Bajic, V. B., Tan, K., Akalin, A., Schmeier, S., Kanamori-Katayama, M., Bertin, N., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.044 · Cited by 715
How the ubiquitin–proteasome system controls transcription
Muratani, M., & Tansey, W. P. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1049 · Cited by 693
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes
Yokoyama, A., & Cleary, M. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.003 · Cited by 555
Roles of p53, MYC and HIF-1 in regulating glycolysis–the seventh hallmark of cancer
Yeung, S. J., Pan, J., & Lee, M.-H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8224-x · Cited by 514
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508 · cited 1×
“In terms of transcription factor inhibition, echinomycin was identified as a HIF1α and HIF1β/DNA binding inhibitor as evidenced using EMSA, luciferase activity and ChIP experiments on HIF-1 response elements (HRE) of the vascular endothelial growth factor promoter (VEGF, associated with tumor vascularization) [277].”
MethodAcute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Erkizan, H. V., Kong, Y., Merchant, M., Schlottmann, S., Barber-Rotenberg, J. S., Yuan, L., Abaan, O. D., Chou, T.-H., Dakshanamurthy, S., Brown, M. L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1983 · Cited by 452
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Kerckaert, J.-P., Deweindt, C., Tilly, H., Quief, S., Lecocq, G., & Bastard, C. (1993) · Nature Genetics · doi:10.1038/ng0993-66 · Cited by 427
Oxidative Stress and Cancer: The Role of Nrf2
Sajadimajd, S., & Khazaei, M. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009617666171002144228 · Cited by 424
Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 397
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M.-P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J. L., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090514 · Cited by 397
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Borkin, D., He, S., Miao, H., Kempinska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.016 · Cited by 392
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.62 · Cited by 389
Baird, L., Llères, D., Swift, S., & Dinkova-Kostova, A. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305687110 · Cited by 380
The ETS family of oncogenic transcription factors in solid tumours
Sizemore, G. M., Pitarresi, J. R., Balakrishnan, S., & Ostrowski, M. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.20 · Cited by 367
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
The role of Nrf2 signaling in counteracting neurodegenerative diseases
Dinkova‐Kostova, A. T., Kostov, R. V., & Kazantsev, A. G. (2018) · The FEBS Journal · doi:10.1111/febs.14379 · Cited by 342
The triple helix: 50 years later, the outcome
Duca, M., Vekhoff, P., Oussedik, K., Halby, L., & Arimondo, P. B. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn493 · Cited by 341
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Blume, S. W., Snyder, R. C., Ray, R., Thomas, S., Koller, C. A., & Miller, D. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115474 · Cited by 333
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Maes, T., Mascaró, C., Tirapu, I., Estiarte, A., Ciceri, F., Lunardi, S., Guibourt, N., Perdones, A., Lufino, M. M. P., Somervaille, T. C. P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.002 · Cited by 323
Role of Carbonic Anhydrase IX in Human Tumor Cell Growth, Survival, and Invasion
Robertson, N., Potter, C., & Harris, A. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2224 · Cited by 304
Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 303
Drug Discovery Targeting Bromodomain-Containing Protein 4
Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01761 · Cited by 303
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
Polo, J. M., Dell'Oso, T., Ranuncolo, S. M., Cerchietti, L., Beck, D., Da Silva, G. F., Prive, G. G., Licht, J. D., & Melnick, A. (2004) · Nature Medicine · doi:10.1038/nm1134 · Cited by 291
Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 291
Echinomycin: a bifunctional intercalating antibiotic
Waring, M. J., & Wakelin, L. P. G. (1974) · Nature · doi:10.1038/252653a0 · Cited by 282
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Yu, W., Chory, E. J., Wernimont, A. K., Tempel, W., Scopton, A., Federation, A., Marineau, J. J., Qi, J., Barsyte-Lovejoy, D., Yi, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms2304 · Cited by 281
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9–mediated leukemogenesis
Nguyen, A. T., Taranova, O., He, J., & Zhang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-334359 · Cited by 275
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R., Casali, P. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2335 · Cited by 267
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Göllner, S., Oellerich, T., Agrawal-Singh, S., Schenk, T., Klein, H.-U., Rohde, C., Pabst, C., Sauer, T., Lerdrup, M., Tavor, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4247 · Cited by 257
Jiang, Z.-Y., Lu, M.-C., Xu, L., Yang, T.-T., Xi, M.-Y., Xu, X.-L., Guo, X.-K., Zhang, X.-J., You, Q.-D., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 252
Santiago, L., Daniels, G., Wang, D., Deng, F., & Lee, P. (2017) · PubMed · Cited by 246
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245 · cited 1×
“This is also the case of PROTACs (for PROteolysis TArgeting Chimeric molecules) such as Cpd 8 [105] that associates Smad3 pocket ligand with HIF1 recognition motif of the von Hippel–Lindau (VHL) E3 ubiquitin ligase [106] or CM11 Homo-PROTAC dimer that induced VHL dimerization and sub-sequent self-degradation [107] (Fi…”
BackgroundREST, a master transcriptional regulator in neurodegenerative disease
Hwang, J.-Y., & Zukin, R. S. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.12.008 · Cited by 245
The Expanding World of N-MYC–Driven Tumors
Rickman, D. S., Schulte, J. H., & Eilers, M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0273 · Cited by 241
NF-kappaB: Two Sides of the Same Coin
Pires, B., Silva, R., Ferreira, G., & Abdelhay, E. (2018) · Genes · doi:10.3390/genes9010024 · Cited by 237
Marcucci, G., Baldus, C. D., Ruppert, A. S., Radmacher, M. D., Mrózek, K., Whitman, S. P., Kolitz, J. E., Edwards, C. G., Vardiman, J. W., Powell, B. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6137 · Cited by 236
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
Xu, B., On, D. M., Ma, A., Parton, T., Konze, K. D., Pattenden, S. G., Allison, D. F., Cai, L., Rockowitz, S., Liu, S., et al. (2015) · Blood · doi:10.1182/blood-2014-06-581082 · Cited by 227
Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition
Gormally, M. V., Dexheimer, T. S., Marsico, G., Sanders, D. A., Lowe, C., Matak-Vinković, D., Michael, S., Jadhav, A., Rai, G., Maloney, D. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6165 · Cited by 224
Kawagoe, H., Humphries, R., Blair, A., Sutherland, H., & Hogge, D. (1999) · Leukemia · doi:10.1038/sj.leu.2401410 · Cited by 223
Olenyuk, B. Z., Zhang, G.-J., Klco, J. M., Nickols, N. G., Kaelin, W. G., & Dervan, P. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407617101 · Cited by 219
Yoshida, H., Kitamura, K., Tanaka, K., Ōmura, S., Miyazaki, T., Hachiya, T., Ohno, R., & Naoe, T. (1996) · PubMed · Cited by 217
Vaswani, R. G., Gehling, V. S., Dakin, L. A., Cook, A. S., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01315 · Cited by 216
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail-Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 214
DOT1L and H3K79 Methylation in Transcription and Genomic Stability
Wood, K., Tellier, M., & Murphy, S. (2018) · Biomolecules · doi:10.3390/biom8010011 · Cited by 209
The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides.
Hélène, C. (1991) · PubMed · Cited by 208
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
Jin, S., Gorfajn, B., Faircloth, G., & Scotto, K. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6775 · Cited by 206
Shi, A., Murai, M. J., He, S., Lund, G., Hartley, T., Purohit, T., Reddy, G., Chruszcz, M., Grembecka, J., & Cierpicki, T. (2012) · Blood · doi:10.1182/blood-2012-05-429274 · Cited by 204
Sprüssel, A., Schulte, J. H., Weber, S., Necke, M., Händschke, K., Thor, T., Pajtler, K. W., Schramm, A., König, K., Diehl, L., et al. (2012) · Leukemia · doi:10.1038/leu.2012.157 · Cited by 203
High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction
Karatas, H., Townsend, E. C., Cao, F., Chen, Y., Bernard, D., Liu, L., Lei, M., Dou, Y., & Wang, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja306028q · Cited by 202
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., & Mantovani, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6780 · Cited by 195
Enhancer of zeste homolog 2 (EZH2) inhibitors
Gulati, N., Béguelin, W., & Giulino-Roth, L. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 193
Nickols, N. G., & Dervan, P. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704217104 · Cited by 189
Siddiquee, K. A. Z., Gunning, P. T., Glenn, M., Katt, W. P., Zhang, S., Schroeck, C., Sebti, S. M., Jove, R., Hamilton, A. D., & Turkson, J. (2007) · ACS Chemical Biology · doi:10.1021/cb7001973 · Cited by 187
What Drives Proteins into the Major or Minor Grooves of DNA?
Privalov, P. L., Dragan, A. I., Crane-Robinson, C., Breslauer, K. J., Remeta, D. P., & Minetti, C. A. S. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.09.059 · Cited by 185
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
Cerchietti, L. C., Yang, S. N., Shaknovich, R., Hatzi, K., Polo, J. M., Chadburn, A., Dowdy, S. F., & Melnick, A. (2009) · Blood · doi:10.1182/blood-2008-07-168773 · Cited by 183
De Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
Hallmarks of glioblastoma: a systematic review
Nørøxe, D. S., Poulsen, H. S., & Lassen, U. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000144 · Cited by 183
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Poole, C. J., & Van Riggelen, J. (2017) · Genes · doi:10.3390/genes8050142 · Cited by 183
Leukaemic transformation by CALM–AF10 involves upregulation of Hoxa5 by hDOT1L
Okada, Y., Jiang, Q., Lemieux, M., Jeannotte, L., Su, L., & Zhang, Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1464 · Cited by 179
Peptide-based inhibitors of protein–protein interactions
Wójcik, P., & Berlicki, Ł. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.084 · Cited by 178
c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Nebbioso, A., Carafa, V., Conte, M., Tambaro, F. P., Abbondanza, C., Martens, J. H. A., Nees, M., Benedetti, R., Pallavicini, I., Minucci, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2388 · Cited by 178
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
Cardenas, M. G., Yu, W., Beguelin, W., Teater, M. R., Geng, H., Goldstein, R. L., Oswald, E., Hatzi, K., Yang, S.-N., Cohen, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85795 · Cited by 176 · cited 3×
“In parallel, synthetic inhibitors were also developed as the indolin derivatives 79-6 and FX1 [172] and the diphenylamine derivative 7 [173] with increasing affinity as exemplify by Molecules 2018, 23, 1479 12 of 51 KD measurement of 129 µM, 7 µM and 78 nM, respectively (Figure 4F).”
BackgroundTargeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia
Cheung, N., Fung, T. K., Zeisig, B. B., Holmes, K., Rane, J. K., Mowen, K. A., Finn, M. G., Lenhard, B., Chan, L. C., & So, C. W. E. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.007 · Cited by 175
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l
Deshpande, A. J., Chen, L., Fazio, M., Sinha, A. U., Bernt, K. M., Banka, D., Dias, S., Chang, J., Olhava, E. J., Daigle, S. R., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465120 · Cited by 174
Interaction of the oligopeptide antibiotics netropsin and distamycin a with nucleic acids
Zimmer, C., Reinert, K. E., Luck, G., Wähnert, U., Löber, G., & Thrum, H. (1971) · Journal of Molecular Biology · doi:10.1016/0022-2836(71)90250-6 · Cited by 174
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Forni, C., Minuzzo, M., Virdis, E., Tamborini, E., Simone, M., Tavecchio, M., Erba, E., Grosso, F., Gronchi, A., Aman, P., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0848 · Cited by 169
Srinivasan, M., & Lahiri, D. K. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.989834 · Cited by 164
The potential role of neuroinflammation and transcription factors in Parkinson disease
Tiwari, P. C., & Pal, R. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/rpal · Cited by 164
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 161
Zhang, W., Xia, X., Reisenauer, M. R., Hemenway, C. S., & Kone, B. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601903200 · Cited by 160
Role of the Keap1–Nrf2 Pathway in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00008-6 · Cited by 158
Hallmarks of cancer progression in Barrett's oesophagus
Morales, C. P., Souza, R. F., & Spechler, S. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11569-8 · Cited by 150
Molecular pathogenesis of multiple myeloma: basic and clinical updates
Chesi, M., & Bergsagel, P. L. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1291-2 · Cited by 149
Shimizu, K., Ichikawa, H., Tojo, A., Kaneko, Y., Maseki, N., Hayashi, Y., Ohira, M., Asano, S., & Ohki, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10280 · Cited by 149
Basavapathruni, A., Jin, L., Daigle, S. R., Majer, C. R., Therkelsen, C. A., Wigle, T. J., Kuntz, K. W., Chesworth, R., Pollock, R. M., Scott, M. P., et al. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12050 · Cited by 147
FoxO transcription factors in cancer metabolism
Yadav, R. K., Chauhan, A. S., Zhuang, L., & Gan, B. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.004 · Cited by 145
Cunningham, L., Finckbeiner, S., Hyde, R. K., Southall, N. T., Marugán, J., Yedavalli, V. R. K., Dehdashti, S., Reinhold, W. C., Alemu, L., Zhao, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200037109 · Cited by 142
Subcellular localization and cytoplasmic complex status of endogenous Keap1
Watai, Y., Kobayashi, A., Nagase, H., Mizukami, M., McEvoy, J. D., Singer, J. D., Itoh, K., & Yamamoto, M. P. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01118.x · Cited by 141
Solution structure of the mithramycin dimer-DNA complex
Sastry, M., & Patel, D. J. (1993) · Biochemistry · doi:10.1021/bi00077a012 · Cited by 141
Chiang, S.-Y., Welch, J., Rauscher, F. J., & Beerman, T. A. (1994) · Biochemistry · doi:10.1021/bi00189a003 · Cited by 139
Dalal, K., Roshan‐Moniri, M., Sharma, A., Li, H., Ban, F., Hessein, M., Hsing, M., Singh, K., Leblanc, E., Dehm, S. M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553818 · Cited by 135
Mithramycin blocks protein binding and function of the SV40 early promoter.
Ray, R. B., Snyder, R. C., Thomas, S. D., Koller, C. A., & Miller, D. M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114110 · Cited by 135
Chen, L., Deshpande, A. J., Banka, D., Bernt, K. M., Dias, S., Buske, C., Olhava, E. J., Daigle, S. R., Richon, V. M., Pollock, R. M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.327 · Cited by 135
Rational Design of Topographical Helix Mimics as Potent Inhibitors of Protein–Protein Interactions
Lao, B. B., Drew, K., Guarracino, D. A., Brewer, T. F., Heindel, D. W., Bonneau, R., & Arora, P. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502310r · Cited by 132
Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
Grohar, P. J., Griffin, L. B., Yeung, C. L., Chen, Q.-R., Pommier, Y. G., Khanna, C., Khan, J. I., & Helman, L. J. (2011) · Neoplasia · doi:10.1593/neo.101202 · Cited by 130
Mode of action of trabectedin in myxoid liposarcomas
Giandomenico, S. D., Frapolli, R., Bello, E., Uboldi, S., Licandro, S. A., Marchini, S., Beltrame, L., Brich, S., Mauro, V., Tamborini, E., et al. (2013) · Oncogene · doi:10.1038/onc.2013.462 · Cited by 130
Drugging the undruggable: Transcription therapy for cancer
Yan, C., & Higgins, P. J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.002 · Cited by 130
Agyeman, A., Jha, B. K., Mazumdar, T., & Houghton, J. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2046 · Cited by 129
Huang, W., Dong, Z., Wang, F., Peng, H., Liu, J., & Zhang, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500071v · Cited by 128
Will, B., Vogler, T. O., Narayanagari, S., Bartholdy, B., Todorova, T. I., da Silva Ferreira, M., Chen, J., Yu, Y., Mayer, J., Barreyro, L., et al. (2015) · Nature Medicine · doi:10.1038/nm.3936 · Cited by 127
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Li, H., Ban, F., Dalal, K., Leblanc, E., Frewin, K., Ma, D., Adomat, H. H., Rennie, P. S., & Cherkasov, A. R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500802j · Cited by 125
A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice
Illendula, A., Pulikkan, J. A., Zong, H., Grembecka, J. E., Xue, L., Sen, S., Zhou, Y., Boulton, A. M., Kuntimaddi, A., Gao, Y., et al. (2015) · Science · doi:10.1126/science.aaa0314 · Cited by 124
Antitumor activity of a pyrrole-imidazole polyamide
Yang, F., Nickols, N. G., Li, B. C., Marinov, G. K., SAID, J. W., & Dervan, P. B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222035110 · Cited by 124
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
Dafflon, C., Craig, V. J., Méreau, H., Gräsel, J., Engstler, B. S., Hoffman, G., Nigsch, F., Gaulis, S., Barys, L., Ito, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.327 · Cited by 123
Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters
Snyder, R. C., Ray, R. B., Blume, S. W., et al. (1991) · Biochemistry · doi:10.1021/bi00231a027 · Cited by 122
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia
Rau, R. E., Rodriguez, B. A., Luo, M., Jeong, M., Rosen, A., Rogers, J. H., Campbell, C. T., Daigle, S. R., Deng, L., Song, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-11-684225 · Cited by 122
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
Bauer, M. R., Joerger, A. C., & Fersht, A. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610421113 · Cited by 122
Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders
Raskatov, J. A., Meier, J. L., Puckett, J. W., Yang, F., Ramakrishnan, P., & Dervan, P. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118506109 · Cited by 121
FOXO transcription factors at the interface of metabolism and cancer
Link, W., & Fernández-Marcos, P. J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30840 · Cited by 121
Pharmacological inhibition of the transcription factor PU.1 in leukemia
Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92504 · Cited by 120
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Gilan, O., Lam, E. Y. N., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C. Y., Ftouni, S., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3249 · Cited by 119
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3168 · Cited by 118
Huang, W., Dong, Z., Chen, Y., Wang, F., Wang, C. J., Peng, H., He, Y., Hangoc, G., Pollok, K. E., Sandusky, G. E., et al. (2015) · Oncogene · doi:10.1038/onc.2015.215 · Cited by 116
Gorczynski, M. J., Grembecka, J. E., Zhou, Y., Kong, Y., Roudaia, L., Douvas, M. G., Newman, M. N., Bielnicka, I., Baber, G. B., Corpora, T., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.09.006 · Cited by 116
Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 116
Targeting acute myeloid leukemia by drug-induced c-MYB degradation
Walf-Vorderwülbecke, V., Pearce, K., Brooks, T., Hubank, M. J. F., van den Heuvel‐Eibrink, M. M., Zwaan, C. M., Adams, S. P., Edwards, D., Bartram, J. L., Samarasinghe, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.317 · Cited by 115
Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer
Huang, L., Walter, V., Hayes, D. N., & Onaitis, M. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2195 · Cited by 114
Flavopiridol binds to duplex DNA.
Bible, K. C., Bible, R. H., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y., Hajdu, E., & Kaufmann, S. H. (2000) · PubMed · Cited by 113
YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion
Rahim, S., Beauchamp, E. M., Kong, Y., Brown, M. L., Toretsky, J. A., & Üren, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019343 · Cited by 113
Matsuda, H., Fukuda, N., Ueno, T., Tahira, Y., Ayame, H., Zhang, W., Bando, T., Sugiyama, H., Saitô, S., Matsumoto, K., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005060650 · Cited by 113
Estève, P., Chin, H. G., & Pradhan, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606203200 · Cited by 111
Wei, Y.-D., Tepperman, K., Huang, M.-Y., Sartor, M. A., & Puga, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310800200 · Cited by 110
The convergent roles of the nuclear factor I transcription factors in development and cancer
Chen, K., Lim, J. W. C., Richards, L. J., & Bunt, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.015 · Cited by 109
Modeling the relationship of epigenetic modifications to transcription factor binding
Liu, L., Jin, G., & Zhou, X. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv255 · Cited by 108
An, Ö., Dall’Olio, G. M., Mourikis, T. P., & Ciccarelli, F. D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1123 · Cited by 106
Regulation of transcription factors by protein degradation
Desterro, J. M. P., Rodríguez, M. S., & Hay, R. T. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000760 · Cited by 105
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Poulain, S., Roumier, C., Bertrand, E., Renneville, A., Caillault, A., Doye, E., Geffroy, S., Sebda, S., Nibourel, O., Nudel, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0007 · Cited by 103
Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1
Barber-Rotenberg, J. S., Selvanathan, S. P., Kong, Y., Erkizan, H. V., Snyder, T. M., Hong, S. P., Kobs, C. L., South, N. L., Summer, S., Monroe, P. J., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.454 · Cited by 101
Karataş, H., Li, Y., Liu, L., Ji, J., Lee, S. H. F., Chen, Y., Yang, J., Huang, L., Bernard, D., Xu, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01796 · Cited by 101
Kaluz, Š., Kaluzová, M., & Stanbridge, E. J. (2003) · PubMed · Cited by 100
He, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401868d · Cited by 99
Fredly, H., Gjertsen, B. T., & Bruserud, Ø. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-12 · Cited by 99
Brambilla, L., Genini, D., Laurini, E., Merulla, J., Perez, L. H., Fermeglia, M., Carbone, G. M., Pricl, S., & Catapano, C. V. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.012 · Cited by 99
Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells
Don‐Doncow, N., Escobar, Z., Johansson, M., Kjellström, S., Garcia, V., Muñóz, E., Sterner, O., Bjartell, A. S., & Hellsten, R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564252 · Cited by 98
Structural Basis for Cyclic Py-Im Polyamide Allosteric Inhibition of Nuclear Receptor Binding
Chenoweth, D. M., & Dervan, P. B. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105068b · Cited by 97
Mutant p53 targeting by the low molecular weight compound STIMA‐1
Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 96
Gupta, A., Bharadwaj, M., Kumar, A., & Mehrotra, R. (2016) · Topics in Current Chemistry · doi:10.1007/s41061-016-0089-0 · Cited by 96
Fossey, S. L., Bear, M. D., Lin, J., Li, C., Schwartz, E. B., Li, P., Fuchs, J. R., Fenger, J. M., Kisseberth, W. C., & London, C. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-112 · Cited by 95
Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
Viziteu, E., Grandmougin, C., Goldschmidt, H., Seckinger, A., Hose, D., Klein, B., & Moreaux, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.20 · Cited by 95
Zhou, H., Liu, L., Huang, J., Bernard, D., Karataş, H., Navarro, A., Lei, M., & Wang, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3015298 · Cited by 94
Polvani, S., Tarocchi, M., Tempesti, S., Bencini, L., & Galli, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2441 · Cited by 94
Harlow, M. L., Maloney, N., Roland, J. T., Navarro, M. J. G., Easton, M. K., Kitchen-Goosen, S. M., Boguslawski, E. A., Madaj, Z., Johnson, B. K., Bowman, M. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0568 · Cited by 93
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 93
Degradation of transcription factor IRF‐1 by the ubiquitin–proteasome pathway
Nakagawa, K., & Yokosawa, H. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01163.x · Cited by 92
Welch, J. J., Rauscher, F. J., & Beerman, T. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47389-9 · Cited by 91
Rao, G., Rekhtman, N., Cheng, G., Krasikov, T., & Skoultchi, A. I. (1997) · Oncogene · doi:10.1038/sj.onc.1200807 · Cited by 89
Functional Enhancers As Master Regulators of Tissue-Specific Gene Regulation and Cancer Development
Ko, J. Y., Oh, S., & Yoo, K. H. (2017) · Molecules and Cells · doi:10.14348/molcells.2017.0033 · Cited by 89
A Hoogsteen base pair embedded in undistorted B-DNA
Aishima, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf661 · Cited by 88
Gibault, F., Bailly, F., Corvaisier, M., Coevoet, M., Huet, G., Melnyk, P., & Cotelle, P. (2017) · ChemMedChem · doi:10.1002/cmdc.201700063 · Cited by 88
Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
González, A. Z., Eksterowicz, J. E., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Duquette, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401767k · Cited by 87
Murakami, S., Ninomiya, W., Sakamoto, E., Shibata, T., Akiyama, H., & Tashiro, F. (2015) · Stem Cells · doi:10.1002/stem.2059 · Cited by 86
Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction
Lemos, A., Leão, M., Soares, J., Palmeira, A., Pinto, M. M. M., Saraiva, L., & Sousa, M. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21393 · Cited by 85
New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation
Wang, X., Feng, S., Fan, J., Li, X., Wen, Q., & Luo, N. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.07.017 · Cited by 84
McCoull, W., Abrams, R., Anderson, E. K., Blades, K., Barton, P., Box, M. R., Burgess, J., Byth, K. F., Cao, Q., Chuaqui, C. E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00359 · Cited by 84
Lu, M., Jiao, Q., Liu, T., Tan, S.-J., Zhou, H.-S., You, Q., & Jiang, Z. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.052 · Cited by 83
Dickinson, L. A., Trauger, J. W., Baird, E. E., Dervan, P. B., Graves, B. J., & Gottesfeld, J. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12765 · Cited by 81
Grohar, P. J., Glod, J. W., Peer, C. J., Sissung, T. M., Arnaldez, F. I., Long, L., Figg, W. D., Whitcomb, P. O., Helman, L. J., & Widemann, B. C. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3382-x · Cited by 81
Yu, J., Li, J., Zhang, S., Xu, X., Zheng, M., Jiang, G., & Li, F. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.046 · Cited by 80
DNA and Non-DNA Targets in the Mechanism of Action of the Antitumor Drug Trabectedin
David‐Cordonnier, M., Gajate, C., Olmea, O., Laine, W., de la Iglesia-Vicente, J., Perez, C., Cuevas, C., Otero, G., Manzanares, I., Bailly, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.08.009 · Cited by 80
Self-citationChen, Q., Xu, R., Zeng, C., Lu, Q., Huang, D., Shi, C., Zhang, W., Deng, L., Yan, R., Rao, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088386 · Cited by 79
Nhili, R., Peixoto, P., Depauw, S., Flajollet, S., Dezitter, X., Munde, M. M., Ismail, M. A., Kumar, A., Farahat, A. A., Stephens, C. E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks971 · Cited by 79
Self-citationKrikun, G., Schatz, F., Mackman, N., Guller, S. M., Demopoulos, R. I., & Lockwood, C. J. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.3.0430 · Cited by 79
Novel DNA Bis-intercalation by MLN944, a Potent Clinical Bisphenazine Anticancer Drug
Dai, J., Punchihewa, C., Mistry, P., Ooi, A. T., & Yang, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404053200 · Cited by 78
Trimmer, E. E., Zamble, D. B., Lippard, S. J., & Essigmann, J. M. (1998) · Biochemistry · doi:10.1021/bi971675q · Cited by 78
Ng, P. Y., Tang, Y., Knosp, W. M., Stadler, H. S., & Shaw, J. T. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700762 · Cited by 77
Targeting HOX/PBX dimers in cancer
Morgan, R., El‐Tanani, M., Hunter, K. D., Harrington, K. J., & Pandha, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15971 · Cited by 76
Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia
Okuda, H., Stanojević, B., Kanai, A., Kawamura, T., Takahashi, S., Matsui, H., Takaori‐Kondo, A., & Yokoyama, A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91406 · Cited by 76
WDR5 high expression and its effect on tumorigenesis in leukemia
Ge, Z., Song, E. J., Kawasawa, Y. I., Li, J., Dovat, S., & Song, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9312 · Cited by 75
Jin, C., Yang, L., Xie, M., Lin, C., Merkurjev, D., Yang, J. C., Tanasă, B., Oh, S., Zhang, J., Ohgi, K. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404303111 · Cited by 74
Cited by
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Therapeutic strategies targeting FOXO transcription factors
Calissi, G., Lam, E. W.-F., & Link, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0088-2 · Cited by 330
The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials
Peng, J., Yang, S., Ng, C. S. H., & Chen, G. G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108333 · Cited by 21
Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H.-Y., & Huang, H. (2021) · doi:10.1101/2021.03.08.434493 · Cited by 2
Metadata
- Authors
- Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-06-19
- Volume
- 23
- Issue
- 6
- Pages
- 1479
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2809413985
- Cited by
- 352
- References
- 377
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.